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Introduction
 Alzheimer’s disease (AD) currently affects 4-8  
% of the population above 65. Or about 3-5 million 
people in the US, making it the most common cause 
of dementia in elderly  people. This number is 
projected to raise from to 25  million patients by 
2050 (1). Symptoms of Alzheimer’s disease include 
memory loss, paranoia, delusions, and declining in 
language function (5).  Although there has been 
some controversy to what  is the cause of AD, there 
is a strong consensus on the lesions that  are 
characteristic of an AD inflicted brain.  First are the 
intracellular neurofibrillary tangles, helical filaments 
formed from a hypophosphorylated form of tau. 
Lastly there are extracellular plaques from deposits 
of amyloid-! peptide.  
 These deposits are formed by the cleavage of an 
amyloid precursor protein  (APP) by !-secretase. 
There are two mechanisms of APP  cleavage that 
may occur.  First  in  the wild type environment 
amyloid-! is created first  by the cleavage of the 
amyloid precursor protein by  !-secretase to form the 
N-terminus and then "-secretase finish off the 
cleavage releasing the mature A!  peptide.  The 
second pathway is used in the environment  without 
!-secretase present.  In this case #-secretase can 
preform the same function as !-secretase (1). 
Although the A!  peptide is created by three proteins, 
only !-secretase cleaves specifically at the Asp +1 
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Abstract
!-Secretase is the enzyme responsible for the Amyloid-! plaques found in Alzheimer’s disease. 
Inhibition of this enzyme should prove to be very useful in combating Alzheimer’s disease by 
preventing this build-up.  After a computational screening of the NCID-2 library a molecule was found 
to possess a 2- propanol structure with aromatic groups on either side. This moiety was replicated by a 
combinatorial library of 150 compounds.  These compounds were screened initially against !-secretase 
at 100, 50, and then 25 µM to narrow down to 17 structures showing 50% inhibition at 25 µM.  The 
IC50 for each of the 17 molecules was found experimentally  resulting in one lead compound 15, 4.93 
µM ± 0.86 µM.  This compound was modified by making slight changes to the 2-propanol moiety 
resulting in mostly loss of activity.
and Glu +11.  "-Secretase cleaves the APP into a 
range of peptides from 38  to 43 residues, but  the 
A!40 is the major product  at 90% abundance.  Albeit 
a minor product  A!42,  at 9% abundance, has been 
shown to be the more pathogenic peptide, giving the 
most to plaque formation (5, 3). 
 !-Secretase was discovered in 1992 and was 
immediately proposed as a target  for Alzheimer’s 
disease.  It wasn’t  definitively characterized until 
1999 when it  was identified by  five different 
research groups using different  methods.  It  was 
named differently by the different groups names 
included BACE (Vasser et al, 1999), !-Secretase, 
(Sinha et al., 1999), Asp2 (Hussain et al., 1999; Yan 
et  al., 1999), and memapsin 2 (Lin et  al., 2000) (1, 
3).  
 Although  many researchers focus drug 
discovery  towards finding the inhibitor with the 
lowest IC50, or binding affinity.  This is only part  of 
whether a compound can become a useable drug. 
The main cause of concern with a prospective drug 
molecule is other properties of the drug with in  the 
patient  including bioavailability and pharmicotoxic 
effects.  
 !-Secretase showed to remain a good drug 
target  not  only because of the evidence between 
amyloid-!  plaques and Alzheimer’s, but  also 
because mice lacking the gene to produce !-
secretase showed no amyloid-!  and initially 
demonstrated no adverse side effects.  Although 
more recents studies with !-secretase knockout mice 
showed a decrease in the myelin sheath layers in 
both peripheral and central nervous cells (2).  When 
further investigated it  was found that  in  the early 
stages of development, when these sheaths first 
form, the concentration of !-secretase was increased 
when compared to that  at latter stages in life.  This is 
proposed to occur by  the cleavage of Neuregulin1 
by !-secretase, whose product  is a growth and 
differentiation  factor that  leads to the formation of 
the myelin sheath. !-Secretase knockout  mice were 
found to have the full length neuregulin1 peptide 
almost  exclusively, while wild type mice had a 
mixture between it  an  the smaller products.  This 
causes decreased hippocampal synaptic plasticity, 
decreased cognitive performance, and reduce 
lifespan (2).  By  nature !-secretase knockout  mice 
imitates inhibition for the entire life cycle. 
Inhibition of !-secretase only latter in life, when 
Alzheimer’s disease predominantly  occurs, cannot 
be measured this way.  These side effects could only 
occur because of the high  rate of myelination 
happening during development.
Fluorescence Resonance Energy Transfer (FRET)
 One of the most difficult  problems to overcome 
when designing a drug is being able to find the 
relevant biological activity of compounds 
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synthesized.  Since !-Secretase is an enzyme there is 
already a biologically relevant  reaction taking place. 
A Fluorescence Resonance Energy Transfer (FRET) 
assay takes advantage of this reaction  to allow for 
the detection of compounds that  would inhibit  this 
enzyme’s active site.  The natural substrate of the 
enzyme (a peptide chain) is modified by first  adding 
a fluorescent  donor to  one side of the molecule and a 
fluorescent  acceptor to  the other side of the chain. 
When this complete molecule is excited by light the 
fluorescent  acceptor effectively quenches the donor 
by resonance energy transfer and no emission is 
seen by the detector.  !-Secretase naturally cleaves 
this peptide substrate.  When this substrate is 
cleaved the donor and acceptor are no longer in 
resonance energy transfer with each other and thus 
when the donor fluorophore is excited by the light  it 
is no longer quenched by the acceptor and thus 
fluoresces (Figure 1).  This emission can be detected 
by a fluorometer, and the intensity of the light 
emitted is directly proportional to the amount of 
substrate being cleaved.  If an inhibitor is placed in 
with the substrate and the protein, the effectiveness 
of the inhibitor and the intensity of the light would 
be inversely related.  By varying the concentration 
of the inhibitor FRET  becomes a powerful tool in 
determining the IC50 values of the compounds.  This 
value represents the concentration needed for the 
50% inhibition of the binding site.
Results 
The initial lead compound was found after 
computational screening of the NCID-2 library, of 
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Figure 1:
Shows the building blocks used to create the combinatorial library.  Each molecule is referenced by the epoxide opening reaction 
between the two building blocks used.
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Figure 2:
Demonstrates the relationship between the NCID-2 hit 
to the combinatorial library synthesized.
1500 diverse compounds against  !-secretase using 
the computer program Maestro.  A molecule was 
shown to bind in the active pocket of !-Secretase 
with a score of -9.73.  This molecule was modeled 
as binding within the pocket using an Aspartate 
residue to hydrogen bond to the hydroxyl group 
of the molecule. This 2-propanol moiety within 
the molecule was used as a starting point to create 
a combinatorially library. 
 The library contained the epoxide opening 
products of 18 epoxides and 23 thiols, a possible 
414  compounds.  Of these 414 compounds 150 
representative compounds were synthesize to test. 
All 150 compounds were tested at  100 µM endpoint, 
of these compounds 42 compounds demonstrated 
50% inhibition or greater.  These compounds were 
tested at 50 µM and 25 µM. 
Epoxide Thiol IC50 BACE1
1 Q U” 10.66 µM ± 1.97 µM
2 S T” 25.43 µM ± 6.08 µM
3 Q T” > 50µM
4 D D” 10.46 µM ± 1.01 µM
5 L W” 10.14 µM ± 1.06 µM
6 G W” 16.85 µM ± 2.81 µM
7 S D” 6.66 µM ± 1.01 µM
8 S U” 12.59 µM ± 2.77 µM
9 A Q” 36.05 µM ± 7.73 µM
10 N L” 8.28 µM ± 0.78 µM
11 N M” 11.00 µM ± 1.36 µM
12 A M” 5.36 µM ± 0.38 µM
13 H L” 7.52 µM ± 1.13 µM
14 Q U” 9.60 µM ± 1.20 µM
15 A D” 4.93 µM ± 0.86 µM
16 S P” 7.09 µM ± 2.36 µM
17 N B” 15.20 µM ± 1.36 µM
Figure 4: IC50 of Best from library
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Figure 3 :
Chart of percent inhibition by each molecule from the combinatorial library at 100 µM.  
"@ 100 uM"
50% 60% 70% 80% 90% Percent Inhibition at 100 µM
A B C D E F G H I J K L M N O P Q R
A” 79.5 83.1 23.2 84 73.6 74.9 68.6 7.9 23.7 34 74.3 -13.2 66.5 77.1
B” 87.7 95.5 29.7 45.2 85.3 83.2 19.6 10 86.7 -8.8 47.8 69.5
C” 85.7 68.9 1.4 85.3 2.3 -3.6 -18.6
D” 78.2 82.3 24 88.7 76.8 16.6 30.3 -26.6 65.5 37.8 72.4 81.6
E”
F” 21.9 63.3
G” 64.1 92.9 58.3 70.9 87 86.1 -61.3 18.8 44.9 -26.5 -8 61.9 53.4
H” 53.8 85.6 9.6 15.1 1.5 87.1 62
I” -28.9 2.8 24.1 10.4 16.4 63.2 81.8
J” 95.9 -15.8 16
K” 10.9
L” 99.7 98.9 44.7 92.2 5.1 81.3
M” 89.1 55.7 32.1 93.9 23.2 0.9 95.4 8 63.7
N” 89.7 14.5 14.9 38.4 7 71.3
O” 71.7 91.9 20.9 -0.9 69.2 78.5
P” 1.1 53.5 -2.9 70.6 79.9
Q” 100 54.7 47.1 73
Y” 51
S” 15 48.4 13.4
T” 61.2 17.8 23.9 33.4 32.4 27.2 2 38 83.8 85.5
U” 74.5 17.4 37.5 19 93.5 85.9
V” 26.5 91.2 10.5 6.7 10.5 76.1
W” 74 91.6 1 24.1 5.4 66.8
  From these compounds the 17  that  showed the 
best  inhibition, 1-17  (Figure 4), were screened at 
multiple concentrations from 100 - 0.001  µM to 
determine the IC50 of the compounds. The 
compound with the best  IC50 was then modified 
around the 2-propanol moiety  to try and target the 
binding of the alcohol to  the active aspartate residue 
in the bridge of the active site.  
 
 
 A variety  of studies on the structure affinity  
relationship centering around the 2-propanol moiety. 
17 modification were complete.  The first study 
examined interaction with the enzymatic aspartate 
residue by modifying the alcohol to a better 
hydrogen donor, amine 26, and then to a hydrogen 
bond acceptor, ketone 27, and modifications on that, 
28-29 (Figure 5).  None of these modifications were 
able to display better  activity than the starting point. 
Structure IC50
26 R1 R2
NH2
15.22 µM ± 4.72 µM
27 R1 R2
O
> 80 µM
28
R1
R2
N
H
NH2 7.47 µM ± 0.83 µM
29
R1
R2
N NH > 50 µM
Figure 5: Modifications altering hydrogen bonding of linker.
 Since the modifications altering the hydrogen 
bonding ability showed no better  improvement in 
binding affinity a second study examining the length 
of the carbon chain between the two aromatic 
groups was examined.  The 2, 3, 4, 5, and 6 carbon 
linker were synthesized, 18-22 (Figure 6), and the 
IC50 were measured for each.  The IC50 was shown 
to decrease from the 2-carbon  to the 4-carbon and 
then begin to increase from the 5-carbon to the 6-
carbon.  
 Third the effect  on the chirality  of the hydroxyl 
group was examined by synthesizing the 
enatiomerically pure S-enantiomer 24, and R-
enantiomer 25.  It  was found that  the S-entantiomer 
showed an  decrease in IC50 while the R-enatiomer 
Structure IC50
18 R2R1 9.37 µM ± 1.21 µM
19 R1 R2 7.19 µM ± 0.60 µM
20 R1 R2 5.64 µM ± 0.43 µM
21 R1 R2 7.22 µM ± 0.84 µM
22 R1 R2 10.04 µM ± 2.69 µM
Figure 6: Modifications in linker length.
Structure IC50
23 R1 R2
OH
7.69 µM ± 0.90 µM
24 R1 R2
OH
5.39 µM ± 0.81 µM
25 R1 R2
OH
7.98 µM ± 1.02 µM
Figure 7: Effect of chirality on activity.
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stayed around the same value as the racemate. 
(Figure 7)
 With the information that the 4-carbon  was the 
ideal length  so a compound containing the 4-carbon 
linker with hydroxyl groups was synthesized, 30, 
but  no increase in binding affinity was observed 
experimentally. Seeing that  the numerous changes in 
the linker were unable to break the IC50 threshold 
held by the original compound, the two dimers of 
the aromatic groups were made. The dimerization of 
the two carbazole groups, 32, showed a much better 
inhibition  than the dimer of the naphthalenethiol 
dimer, 33, but  only a slight increase in inhibition 
than the original compound 23. The 4-carbon diol of 
the carbazole dimer was also synthesized, 31, 
applying the ideal linker length found to the ideal 
side group found, but no increase in inhibition was 
observed.
Structure IC50
30 R1 R2
OH
OH
10.42 µM ± 1.45 µM
31 R1 R1
OH
OH
8.10 µM ± 1.78 µM
32 R1 R1
OH
4.18 µM ± 0.98 µM
33 R2 R2
OH
> 30 µM
Figure 8
Conclusions
 In conclusion a new class of small molecule 
inhibitors was described and characterized.  The 
structure activity relationship of the molecules has 
been  investigated by varying both the side groups 
and the linker between the side groups in  both size 
and functionality. 
Methods
BACE1 Assay. Inhibition was determined using 
the Panvera BACE1 (!-Secretase) FRET  Assay Kit, 
Red (P2985) sold by  Invitrogen.  In an opaque flat 
bottom 384 microtiter plate the inhibitor was diluted 
from 3 mM DMSO solution to the desired 
concentration in acetate Buffer so that  no more than 
10% DMSO existed in  the sample.  10 µL of 
BACE1 substrate (3X solution, 750 nM) was plated 
into wells containing 10  µL of inhibitor at  3X 
concentration. 10 µL of !-Secretase enzyme solution 
(3X solution, 1.0 unit/mL) was added and the 
microtiter plate was let  sit  in  the dark at room 
temperature.  After 1 hour an endpoint  reading was 
measured.  This number was corrected from  RFU to 
percent  inhibition based on a Positive control (10% 
DMSO in Buffer, !-Secretase Substrate, and !-
Secretase protein solution) representing 0% 
inhibition, and Negative control (10% DMSO in 
Buffer, !-Secretase Substrate) representing 100% 
inhibition. For IC50 determination  the inhibitor is 
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measured at  multiple concentrations (100, 50, 10, 5, 
1, 0.1, 0.01, 0.001µM) which are then corrected by 
the positive and negative controls and then fitted to 
the Hills plot  and solved by using the program 
SigmaPlot®. If the measured Hill plot  gave an  error 
greater than 15 % the region in  the plot  where 
percent  inhibition  jumps sharply is expanded so that 
there are more points between the lowest  and 
highest percent  inhibition.  If this did not  yield a 
better curve then the inhibitor is diluted in  less than 
1% methanol instead of DMSO.
Synthesis. The majority of products, 1-17, were 
produced by  the nucleophilic epoxide opening 
reaction  of an epoxide prepared by the substitution 
of epichlorohyrin, and a commercially available 
thiol (Scheme 1) . Enantiomerical ly pure 
compounds, 24-25, were synthesized through the 
use of enatiometrically pure epichlorohydrin in the 
epoxide opening (Scheme 1). Linker chain 
extensions, 18-22,  were prepared by the substitution 
of the dihalide of the linker with carbazole creating 
a monohalide, then substituted with the 2-
naphthalenethiol (Scheme 2).  It  was observed that 
the reaction scheme 2 was highly  dependent  on  the 
substrate.  Different haloalkanes had to be used for 
different  size chains, this was due to the elimination 
product of the dihalide being in competition with  the 
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Figure 9 : Synthetic schemes used.
(a) KOH, (Pr)4NI, RT, 2hr. (b) 9:1 EtOH:H2O, reflux, 14 hr. (c) KOH, DMF, rt 16h. (d)K2CO3, DMF, rt ---> 85oC, 16h. (e)
Dess.Martin Periodinone, dry DCM, 1h. (f) Acetic acid, MeOH, 2h. (g) NaCHBH3 (h) 2M HCl in ether, 2h. (j)DCM, DMF, 
SOCl2, 0oC ---> 45oC, 4h. (k) NH3 (liq), DMF, -50oC ---> rt, 2 days. (l) NaH, DMF, 0oC ---> rt, 10 min. (m) 0oC, 3 hr. (n) 
mCPBA, DCM, NaHCO3, 0oC ---> rt, 16h. (o) KOH, iPrOH, H2O, reflux, 24h. (p) KOtBu, tBuOH. 
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desired reaction.  With smaller alkanes it was 
necessary  to  use the less reactive chloroalkane while 
this reacted too slow for the larger chains so the 
iodoalkane was used.  The 2-carbon used the 
d i c h l o r o e t h a n e , t h e 3 - c a r b o n  u s e d t h e 
dibromopropane, and the 4-carbon used the 
diiodobutane. The 5 and 6 carbon chains were 
especially difficult, a 1-chloro-5-iodopentane (1-
chloro-6-iodohexane) was used first  to couple to the 
carbazole and then the chloro was replace by an 
iodine using NaI in acetone which was then reacted 
with the naphthalene thiol to produce 21 (and 22 
respectively).  The ketone, 27, was produce by 
oxidation of compound 23  with the Dess Martin 
Periodinone (Scheme 3).  Compounds 26  and 29 
were produced by in situ substitution of the 
chlorinated compound 23 by scheme 4. 28 was 
syn thes ized by the epox ide open ing o f 
butadienemonooxide with carbazole and then the 
epoxidation of the produced alkene with mCPBA 
(Scheme 6). 31 was made using the  double epoxide 
opening of 2,2’-bioxirane by carbazole (Scheme 8). 
Both 32  and 33 were made by substituting the 
epibromohydrin while opening the epoxide in 
simultaneously to create the dimers (Scheme 7). 
Further Studies
 To ensure that  the best inhibitors found could be 
good drug molecules many more experiments must 
be completed.  First  of all the selectivity of the 
inhibitors must  be established, this will be done by 
investigating the activity  against  similar proteases 
such as renin  and Cathepsin D. Next the 
bioavailability must  be modeled, this will be done 
by measuring the logD at  multiple physiological 
pHs.  To model the blood brain barrier the inhibitors 
will be subjected to a PAMPA (Parallel Artificial 
Membrain Permiabillity Assay).  Lastly  to help 
ensure good activity the inhibitors will be modeled 
via in silico methods.
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Original screening IC50 Compounds
4-(3-(4-benzylphenoxy)-2-hydroxypropylthio)phenol (1) :
1H NMR (400 MHz, CDCl3): ! 7.33 – 7.23 (m, 4H), 7.21-7.16 (m, 3H), 7.08 (d, J = 8.5, 
2H), 6.78 (d, J = 8.5, 2H), 6.70 (d, J = 8.6, 1H), 5.97 (s, 1H), 4.03-3.94 (m, 3H), 3.91 (s, 
2H), 3.12 – 2.97 (m, 3H).  13C NMR (100 MHz, CDCl3): !C (ppm)  156.9, 155.9, 
141.7, 134.1, 133.2, 130.2, 129.0, 128.7, 126.3, 124.9, 116.6, 114.8, 70.3, 68.9, 41.3, 
39.7.  
2-(2-hydroxy-3-(2-phenyl-1H-indol-1-yl)propylthio)phenol (2) : 1H NMR (400 MHz, 
CDCl3) ! 7.62 (d, J = 7.7 Hz, 1H), 7.46 – 7.33 (m, 6H), 7.30 – 7.19 (m, 3H), 7.15 (t, J = 
7.4 Hz, 1H), 6.98 (s, 1H), 6.93 (d, J = 7.9 Hz, 1H), 6.81 (t, J = 7.5 Hz, 1H), 6.54 (s, 1H), 
4.21 (qd, J = 14.8, 6.3 Hz, 2H), 3.85 (d, J = 2.7 Hz, 1H), 2.68 – 2.43 (m, J = 13.7, 6.0 Hz, 
3H). 13C NMR (100 MHz, CDCl3): !C (ppm) 157.3, 141.6, 138.0, 136.2, 132.9, 131.6, 
129.9, 128.9, 128.5, 122.3, 121.1, 120.9, 120.5, 118.6, 115.8, 110.6, 103.5, 69.5, 48.8, 
41.1 
1-(4-benzylphenoxy)-3-(1-phenyl-1H-tetrazol-5-ylthio)propan-2-ol (3) :
1H NMR (400 MHz, CDCl3): ! 7.52 (dd, J = 7.7, 1.4, 1H), 7.36 – 7.16 (m, 6H), 7.10 (d, 
J = 8.5, 2H), 7.01 (d, J = 7.5, 1H), 6.87 (t, J = 7.5, 1H), 6.80 (d, J = 8.5, 2H), 4.06 – 3.88 
(m, 6H), 3.11 (s, 1H), 3.00 (dd, J = 13.7, 4.3, 1H), 2.89 (dd, J = 13.7, 8.0, 1H).  13C 
NMR (100 MHz, CDCl3): !C (ppm)157.7, 156.9, 141.7, 136.6, 134.4, 131.7, 130.2, 
129.1, 128.7, 126.3, 121.1, 118.7, 115.9, 114.8, 70.7, 68.8, 41.3, 40.1.  
1-(1H-indol-1-yl)-3-(naphthalen-2-ylthio)propan-2-ol (4) :
1H NMR (400 MHz, CDCl3) ! 7.83 – 7.64 (m, 5H), 7.54 – 7.45 (m, 2H), 7.45 – 7.37 (m, 
1H), 7.35 (d, J = 8.0, 1H), 7.25 – 7.10 (m, 3H), 6.55 (t, J = 6.3, 1H), 4.31 (dd, J = 14.2, 
4.3, 1H), 4.12 (m, 2H), 3.10 (dd, J = 13.9, 4.9, 1H), 2.96 (dd, J = 13.9, 7.2, 1H), 2.81 – 
2.16 (m, 1H).  13C NMR (100 MHz, CDCl3): !C (ppm) 136.4, 133.8, 132.2, 132.1, 
128.9, 128.8, 128.7, 127.9, 126.9, 126.2, 121.9, 121.2, 119.8, 109.6, 101.9, 69.3, 50.8, 
38.5.  
1-(9H-carbazol-9-yl)-3-(naphthalen-2-ylthio)propan-2-ol (23) .
1H NMR (400 MHz, CDCl3) ! 8.12 – 8.06 (m, 2H), 7.79 – 7.71 (m, 1H), 7.69 (d, J = 8.5 
Hz, 1H), 7.61 (s, 1H), 7.55 – 7.31 (m, 8H), 7.29 - 7.23 (m, 2H), 4.51 – 4.42 (m, 1H), 4.42 
– 4.34 (m, 1H), 4.29 (s, 1H), 3.21 - 3.16 (m, 1H), 3.11 – 3.00 (m, 1H), 2.57 (s, 1H).13C 
NMR (100 MHz, CDCl3): !C (ppm) 140.9, 133.8, 132.3, 132.1, 128.9, 127.8, 127.7, 
127.4, 127.3, 126.8, 126.2, 126.1, 123.2, 120.5, 119.5, 109.2, 69.2, 48.0, 38.8
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N
S
HO
N
S
OH
1-(2,3-dihydrocyclopenta[b]indol-4(1H)-yl)-3-(o-tolylthio)propan-2-ol (5) : 1H NMR 
(400 MHz, CDCl3) ! 7.46 (d, J = 6.7 Hz, 1H), 7.27 (d, J = 7.4 Hz, 1H), 7.18 (dd, J = 
14.2, 6.2 Hz, 2H), 7.15 – 7.07 (m, 4H), 4.21 (dd, J = 16.7, 7.4 Hz, 1H), 4.10 (t, J = 8.2 
Hz, 2H), 3.07 – 3.00 (m, 1H), 2.93 (d, J = 6.5 Hz, 1H), 2.87 (dd, J = 14.1, 7.2 Hz, 4H), 
2.55 (dd, J = 13.4, 6.8 Hz, 2H), 2.46 – 2.37 (m, 4H). 13C NMR (101 MHz, CDCl3): !C 
(ppm) 146.5, 141.3, 138.3, 134.2, 130.6, 128.9, 126.7, 126.6, 124.8, 120.4, 119.5, 118.8, 
118.6, 109.9, 69.5, 49.6, 38.1, 28.5, 25.6, 24.8, 20.6.
1-(naphthalen-2-ylthio)-3-(2-phenyl-1H-indol-1-yl)propan-2-ol (7) : 1H NMR (400 
MHz, CDCl3) ! 7.83 – 7.76 (m, 1H), 7.72 – 7.65 (m, 2H), 7.64 – 7.57 (m, 1H), 7.54 – 
7.34 (m, 9H), 7.27 – 7.15 (m, 3H), 6.59 (s, 1H), 4.40 – 4.35 (m, 2H), 4.04-3.99 (m, 1H), 
2.88 (dd, J = 14.0, 4.2 Hz, 1H), 2.74 (dd, J = 14.0, 8.2 Hz, 1H), 2.38 (d, J = 3.6 Hz, 1H). 
13C NMR (100 MHz, CDCl3): !C (ppm) 141.7, 138.0, 133.9, 133.0, 132.4, 132.2, 
129.9, 128.9, 128.9, 128.5, 128.4, 127.9, 127.7, 127.5, 127.4, 126.9, 126.2, 122.3, 120.1, 
120.5, 110.7, 103.5, 69.0, 48.7, 38.9
4-(2-hydroxy-3-(2-phenyl-1H-indol-1-yl)propylthio)phenol (8) : 1H NMR (400 MHz, 
CDCl3) ! 7.61 (d, J = 7.7 Hz, 1H), 7.48 – 7.32 (m, 6H), 7.27 – 7.09 (m, J = 24.2, 17.4, 
10.3 Hz, 2H), 7.03 (d, J = 8.6 Hz, 2H), 6.61 (d, J = 8.6 Hz, 2H), 6.52 (s, 1H), 5.42 (s, 
1H), 4.29 (d, J = 6.3 Hz, 2H), 3.85 (s, 1H), 2.60 (qd, J = 13.9, 6.2 Hz, 2H), 2.46 – 2.33 
(m, J = 2.0 Hz, 1H). 13C NMR (100 MHz, CDCl3): !C (ppm) 155.6, 141.7, 138.0, 
133.8, 133.0, 129.9, 128.8, 128.4, 128.3, 124.8, 122.1, 120.9, 120.4, 116.5, 110.6, 103.3, 
69.1, 48.6, 41.0
1-(3-aminophenylthio)-3-(9H-carbazol-9-yl)propan-2-ol (9) :
1H NMR (400 MHz, CDCl3) ! 8.09 (d, J = 7.7 Hz, 2H), 7.50 – 7.38 (m, 4H), 7.26 - 7.21 (m, 2H), 
6.97 (t, J = 7.8 Hz, 1H), 6.64 (d, J = 7.7 Hz, 1H), 6.45 – 6.31 (m, 2H), 4.45 (dd, J = 14.9, 5.6 Hz, 
1H), 4.38 (dd, J = 14.9, 6.5 Hz, 1H), 4.32 – 4.18 (m, 1H), 3.38 (s, 1H), 3.04 (dd, J = 14.0, 4.7 Hz, 
1H), 2.91 (dd, J = 14.0, 7.5 Hz, 1H), 2.66 (s, 1H). 13C NMR (100 MHz, CDCl3): 147.2, 
140.9, 135.7, 130.1, 126.1, 123.2, 120.5, 119.5, 115.3, 113.6, 109.3, 69.2, 47.9, 38.7.
1-(2-chlorophenylthio)-3-(3,4-dihydro-1H-carbazol-9(2H)-yl)propan-2-ol (10) : 1H 
NMR (400 MHz, CDCl3) ! 7.48 (d, J = 7.3 Hz, 0H), 7.41 – 7.35 (m, 0H), 7.26 (d, J = 7.7 
Hz, 0H), 7.17 – 7.06 (m, 2H), 4.25 – 4.01 (m, 3H), 3.08 (dd, J = 13.7, 4.3 Hz, 1H), 2.96 
(dd, J = 13.7, 7.2 Hz, 1H), 2.82 – 2.59 (m, 4H), 2.44 (d, J = 3.2 Hz, 1H), 2.00 – 1.79 (m, 
4H). 13C NMR (100 MHz, CDCl3): !C (ppm) 136.7, 135.9, 134.6, 134.5, 130.2, 129.7, 
127.8, 127.6, 127.5, 121.1, 119.3, 118.2, 110.4, 109.2, 69.6, 47.9, 38.0, 23.5, 23.4, 22.7, 
21
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1-(3,4-dihydro-1H-carbazol-9(2H)-yl)-3-(2-fluorophenylthio)propan-2-ol (11) : 1H 
NMR (400 MHz, CDCl3) ! 7.47 (d, J = 7.6 Hz, 0H), 7.33 (t, J = 7.6 Hz, 0H), 7.26 (t, J = 
8.2 Hz, 1H), 7.17 – 7.02 (m, 1H), 4.19 (dd, J = 13.8, 3.6 Hz, 1H), 4.06 (dd, J = 21.7, 7.9 
Hz, 2H), 3.11 – 3.02 (m, J = 9.5, 4.9 Hz, 1H), 2.94 (dd, J = 13.6, 7.1 Hz, 1H), 2.81 – 2.60 
(m, 4H), 2.44 (s, 1H), 2.00 – 1.81 (m, 4H). 13C NMR (100 MHz, CDCl3): !C (ppm) 
136.7, 136.0, 133.0, 129.6, 129.4, 127.8, 125.0, 121.0, 119.2, 118.1, 116.3, 116.1, 110.3, 
109.2, 69.9, 47.8, 38.8, 23.5, 23.4, 22.7, 21.3.
1-(9H-carbazol-9-yl)-3-(2-fluorophenylthio)propan-2-ol (12) :
1H NMR (400 MHz, CDCl3) ! 8.07 (d, J = 7.7, 2H), 7.43 (d, J = 3.3, 4H), 7.32 (t, J = 7.5, 
1H), 7.28 – 7.18 (m, 3H), 7.10 – 6.96 (m, 2H), 4.49 (dd, J = 15.0, 4.5, 1H), 4.40 (dd, J = 
15.0, 6.8, 1H), 4.19 (m, 1H), 3.13 (dd, J = 13.7, 4.7, 1H), 2.99 (dd, J = 13.7, 7.5, 1H), 
2.44 (s, 1H).  13C NMR (100 MHz, CDCl3): !C (ppm) 141.0, 133.4, 129.7, 129.6, 
126.1, 124.9, 123.2, 120.5, 119.6, 116.3, 116.1, 109.2, 69.6, 48.0, 39.22.  
1-(2-chlorophenylthio)-3-(6-ethyl-1H-indol-1-yl)propan-2-ol (13) :
1H NMR (400 MHz, CDCl3): ! 7.49 (d, J = 7.7, 1H), 7.38 (d, J = 7.5, 1H), 7.14 – 6.97 
(m, 6H), 6.52 (d, J = 2.8, 1H), 4.50 (dd, J = 14.8, 4.5, 1H), 4.29 (dd, J = 14.8, 7.6, 1H), 
4.00 (m, 1H), 3.05 – 2.90 (m, 4H), 2.44 (d, J = 3.5, 1H), 1.33 – 1.26 (m, 3H).   13C 
NMR (100 MHz, CDCl3): !C (ppm) 134.4, 134.3, 134.1, 130.6, 130.2, 129.5, 127.6, 
123.2, 120.4, 119.5, 102.7, 70.4, 53.7, 37.5, 26.0, 15.9.  
1-(4-benzylphenoxy)-3-(2-chlorophenylthio)propan-2-ol (14) :
1H NMR (400 MHz, CDCl3): ! 7.38 (dd, J = 14.7, 7.8, 2H), 7.30 – 7.23 (m, 2H), 7.21 – 
7.12 (m, 4H), 7.09 (d, J = 7.6, 3H), 6.82 (t, J = 9.4, 2H), 4.17 – 3.95 (m, 3H), 3.92 (s, 
2H), 3.27 (dd, J = 13.7, 5.4, 1H), 3.15 (dd, J = 13.6, 6.7, 1H), 2.74 (s, 1H).  13C NMR 
(100 MHz, CDCl3): !C (ppm)  157.2, 156.9, 141.7, 134.7, 134.6, 134.2, 130.2, 130.0, 
129.0, 128.7, 127.6, 127.5, 126.2, 114.8, 70.4, 68.8, 41.2, 36.7.  
1-(9H-carbazol-9-yl)-3-(naphthalen-2-ylthio)propan-2-ol (15) :
1H NMR (400 MHz, CDCl3): ! 8.11 (d, J = 7.7, 2H), 7.76 (d, J = 7.9, 1H), 7.69 (d, J = 
8.6, 1H), 7.62 (s, 1H), 7.56 – 7.33 (m, 8H), 7.26 (m, 2H), 4.47 (dd, J = 14.9, 5.0, 1H), 
4.38 (dd, J = 14.8, 6.7, 1H), 4.33 – 4.25 (m, 1H), 3.18 (dd, J = 13.9, 4.7, 1H), 3.06 (dd, J 
= 13.8, 7.3, 1H), 2.73 – 2.44 (m, 1H).  13C NMR (100 MHz, CDCl3): !C (ppm) 141.0, 
133.9, 132.4, 132.2, 129.0, 127.9, 127.8, 127.5, 127.4, 126.9, 126.3, 126.2, 123.3, 120.6, 
119.6, 109.3, 69.3, 48.1, 38.9.  
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1-(2-ethylphenylthio)-3-(2-phenyl-1H-indol-1-yl)propan-2-ol (16) : 1H NMR (400 
MHz, CDCl3) ! 7.68 (d, J = 7.7 Hz, 0H), 7.56 – 7.38 (m, 2H), 7.31 – 7.12 (m, 1H), 7.10 – 
7.01 (m, 0H), 6.95 (d, J = 7.8 Hz, 0H), 6.61 (s, 0H), 4.40 – 4.33 (m, 2H), 4.07 – 3.95 (m, 
1H), 2.84 – 2.63 (m, 4H), 2.35 (d, J = 3.5 Hz, 1H), 1.23 (t, J = 7.5 Hz, 3H).  13C NMR 
(100 MHz, CDCl3): !C (ppm) 144.1, 141.8, 138.1, 133.7, 133.1, 130.0, 129.0, 128.9, 
128.5, 128.4, 126.8, 126.8,122.2, 121.0, 120.5, 110.8, 103.5, 69.13, 48.8, 38.6, 27.1, 15.0
1-(3,4-dihydro-1H-carbazol-9(2H)-yl)-3-(4-methoxyphenylthio)propan-2-ol (17) : 1H 
NMR (400 MHz, CDCl3) ! 7.45 (d, J = 7.3, 1H), 7.31 (d, J = 8.7, 2H), 7.26 – 7.20 (m, 
1H), 7.12-7.04 (m, 2H), 6.81 (d, J = 8.7, 2H), 4.21 – 4.10 (m, 1H), 4.07-4.00 (m, 2H), 
3.78 (s, 3H), 2.97 (dd, J = 13.7, 4.5, 1H), 2.85 (dd, J = 13.7, 7.3, 1H), 2.78 – 2.58 (m, 
4H), 2.46 (s, 1H), 1.97 – 1.78 (m, 4H).  13C NMR (100 MHz, CDCl3): !C (ppm)159.6, 
136.7, 136.0, 133.7, 127.7, 125.1, 121.0, 119.2, 118.0, 115.1, 110.2, 109.2, 69.6, 55.6, 
47.8, 41.1, 23.5, 23.4, 22.7, 21.3.  
Modification of Combinatorial Library
9-(2-(naphthalen-2-ylthio)ethyl)-9H-carbazole (18) : 
1H NMR (400 MHz, CDCl3) ! 8.08 – 8.02 (m, 2H), 7.83-7.72 (m, 4H), 7.54 – 7.39 (m, 
5H), 7.31 – 7.20 (m, 4H), 4.56 – 4.49 (m, 2H), 3.43 – 3.36 (m, 2H). 13C NMR (100 
MHz, CDCl3): !C (ppm) 140.0, 133.7, 132.2, 132.1, 128.7, 128.0, 127.8, 127.5, 127.1, 
126.7, 126.0, 125.7, 123.0, 120.4, 119.2, 108.4, 42.5, 31.8. 
9-(3-(naphthalen-2-ylthio)propyl)-9H-carbazole (19) :
1H NMR (400 MHz, CDCl3) ! 8.19 – 8.13 (m, 2H), 7.82 – 7.77 (m, 1H), 7.74 (dd, J = 
8.5, 3.8 Hz, 1H), 7.70 – 7.60 (m, 2H), 7.52 – 7.38 (m, 7H), 7.32 – 7.26 (m, 2H), 4.49 - 
4.46 (m, 2H), 3.03 – 2.97 (m, 2H), 2.30 – 2.22 (m, 2H).  13C NMR (100 MHz, CDCl3): 
!C (ppm) 140.4, 133.8, 133.2, 131.8, 128.6, 127.7, 127.4, 127.2, 127.1, 126.6, 125.8, 
125.8, 123.0, 120.5, 119.1, 108.7, 41.3, 30.8, 28.1. 
9-(4-(naphthalen-2-ylthio)butyl)-9H-carbazole (20) :
1H NMR (400 MHz, CDCl3) ! 8.13 (dd, J = 7.8, 0.7 Hz, 2H), 7.84 – 7.79 (m, 1H), 7.73 
(dd, J = 6.1, 5.6 Hz, 2H), 7.53 – 7.44 (m, 3H), 7.42 – 7.36 (m, 2H), 7.31 – 7.23 (m, 2H), 
4.29 (t, J = 7.1 Hz, 2H), 2.99 (t, J = 7.1 Hz, 2H), 2.12 – 2.01 (m, 2H), 1.79 - 1.72 (m, 
2H).  13C NMR (100 MHz, CDCl3): !C (ppm) 140.5, 133.9, 133.9, 131.9, 128.6, 127.9, 
127.7, 127.4, 127.2, 126.7, 125.8, 125.8, 123.0, 120.5, 119.0, 108.7, 42.7, 33.6, 28.1, 
26.8. 
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9-(5-(naphthalen-2-ylthio)pentyl)-9H-carbazole (21) :
1H NMR (400 MHz, cdcl3) ! 8.16 (d, J = 7.8 Hz, 2H), 7.83 – 7.73 (m, 4H), 7.53 – 7.38 
(m, 7H), 7.32 – 7.25 (m, 2H), 4.28 (t, J = 7.1 Hz, 2H), 2.97 (t, J = 10.3, 2H), 1.94 – 1.85 
(m, 2H), 1.79 – 1.67 (m, 2H), 1.59 – 1.48 (m, 2H).  13C NMR (100 MHz, CDCl3): !C 
(ppm) 140.5, 134.3, 133.9, 131.8, 128.5, 127.9, 127.4, 127.2, 126.8, 126.7, 125.8, 125.7, 
123.0, 120.5, 119.0, 108.8, 42.9, 33.4, 29.1, 28.7, 26.6. 
9-(6-(naphthalen-2-ylthio)hexyl)-9H-carbazole (22) : 
1H NMR (400 MHz, cdcl3) ! 8.14 (dd, J = 7.7, 0.6 Hz, 2H), 7.82 – 7.71 (m, 4H), 7.51 – 
7.37 (m, 7H), 7.29 – 7.24 (m, 2H), 4.28 (t, J = 7.1 Hz, 2H), 2.98 (t, J = 7.2 Hz, 2H), 1.91 
- 1.84 (m, 2H), 1.72 – 1.63 (m, 2H), 1.54 – 1.45 (m, 2H), 1.43 - 1.36 (m, 2H).  13C NMR 
(100 MHz, CDCl3): !C (ppm) 140.6, 135.6, 134.0, 131.8, 128.5, 127.9, 127.3, 127.1, 
126.7, 126.5, 125.8, 125.7, 123.0, 120.5, 118.9, 108.8, 43.0, 33.5, 29.1, 29.0, 28.7, 27.0. 
1-(9H-carbazol-9-yl)-3-(naphthalen-2-ylthio)propan-2-one (27) :
1H NMR (400 MHz, cdcl3) ! 8.10 – 8.06 (m, 2H), 7.81 – 7.68 (m, 4H), 7.52 – 7.45 (m, 
2H), 7.39 – 7.33 (m, 3H), 7.27 - 7.23 (m, 2H), 7.13 (d, J = 8.2 Hz, 2H), 5.12 (s, 2H), 3.66 
(s, 2H). 13C NMR (100 MHz, CDCl3): !C (ppm) 200.6, 140.5, 133.8, 132.4, 131.4, 
129.2, 128.8, 127.9, 127.5, 127.5, 127.0, 126.5, 126.2, 123.4, 120.7, 120.0, 108.5, 50.8, 
40.8. 
(S)-1-(9H-carbazol-9-yl)-3-(naphthalen-2-ylthio)propan-2-ol (24) .
1H NMR (400 MHz, CDCl3) ! 8.10 - 8.07 (m, 2H), 7.77 – 7.66 (m, 2H), 7.62 (s, 1H), 
7.54 – 7.48 (m, 1H), 7.47 – 7.33 (m, 7H), 7.25 - 7.21 (m, 2H), 4.52 (dd, J = 14.9, 5.3 Hz, 
1H), 4.47 – 4.39 (m, 1H), 4.32 (s, 1H), 3.25 - 3.19 (m, 1H), 3.12 – 3.04 (m, 1H), 2.47 (d, 
J = 3.6 Hz, 1H).  13C NMR (100 MHz, CDCl3): !C (ppm) 140.9, 133.9, 132.3, 132.2, 
129.0, 127.9, 127.8, 127.5, 127.4, 126.9, 126.3, 126.1, 123.3, 120.6, 119.6, 109.2, 69.2, 
48.0, 39.0. 
(R)-1-(9H-carbazol-9-yl)-3-(naphthalen-2-ylthio)propan-2-ol (25) .
1H NMR (400 MHz, CDCl3) ! 8.11 – 8.07 (m, 2H), 7.77 – 7.72 (m, 1H), 7.69 (d, J = 8.8 
Hz, 1H), 7.62 (d, J = 1.4 Hz, 1H), 7.54 – 7.49 (m, 1H), 7.46 – 7.34 (m, 7H), 7.25 - 7.21 
(m, 2H), 4.52 (dd, J = 14.9, 5.4 Hz, 1H), 4.43 (dd, J = 14.9, 6.6 Hz, 1H), 4.32 (s, 1H), 
3.22 (dd, J = 13.9, 4.8 Hz, 1H), 3.09 (dd, J = 14.0, 7.5 Hz, 1H), 2.46 (d, J = 2.9 Hz, 1H).  
13C NMR (100 MHz, CDCl3): !C (ppm) 140.9, 133.9, 132.2, 132.2, 129.0, 127.9, 127.6, 
127.4, 126.9, 126.3, 126.1, 123.3, 120.6, 119.6, 109.2, 69.2, 48.0, 39.1. 
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Supporting Information of BACE1 Assay
1  IC50 = 10.66 !M ± 1.97 !M
2  IC50 = 25.43 !M ± 6.08 !M
4   IC50 = 10.46 !M ± 0.88 !M
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5  IC50 = 10.14 !M ± 1.06 !M
6  IC50 = 16.85 !M ± 2.81 !M
7  IC50 = 6.66 !M ± 1.01 !M
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8  IC50 = 12.59 !M ± 2.77 !M
9  IC50 = 36.05 !M ± 7.73 !M
   
10  IC50 = 8.28 !M ± 0.78 !M
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11  IC50 = 11.00 !M ± 1.36 !M
12  IC50 = 5.36 !M ± 0.38 !M
13  IC50 = 7.52 !M ± 1.13 !M
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14  IC50 = 9.60 !M ± 1.20 !M
15  IC50 = 4.93 !M ± 0.86 !M
16  IC50 = 7.09 !M ± 2.36 !M
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17  IC50 = 15.20 !M ± 1.36 !M
Modifications 
Modifications from original combinatorial library. Compounds (18-32)
32  IC50 = 4.18 !M ± 0.98 !M
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18  IC50 = 9.37 !M ± 1.21 !M
19  IC50 = 7.19 !M ± 0.60 !M
20  IC50 = 5.64 !M ± 0.43 !M
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21  IC50 = 7.22 !M ± 0.84 !M
22  IC50 = 10.04 !M ± 2.69 !M
 
24  IC50 = 5.39 !M ± 0.81 !M
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25  IC50 = 7.98 !M ± 1.02 !M
31  IC50 = 8.10 !M ± 1.78 !M
23  IC50 = 7.69 !M ± 0.90 !M
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30  IC50 = 10.42 !M ± 1.45 !M
28  IC50 = 7.47 !M ± 0.83 !M
26  IC50 = 15.22 !M ± 4.72 !M
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"@ 100 uM"
50% 60% 70% 80% 90% Percent Inhibition at 100 µM
A B C D E F G H I J K L M N O P Q R
A” 79.5 83.1 23.2 84 73.6 74.9 68.6 7.9 23.7 34 74.3 -13.2 66.5 77.1
B” 87.7 95.5 29.7 45.2 85.3 83.2 19.6 10 86.7 -8.8 47.8 69.5
C” 85.7 68.9 1.4 85.3 2.3 -3.6 -18.6
D” 78.2 82.3 24 88.7 76.8 16.6 30.3 -26.6 65.5 37.8 72.4 81.6
E”
F” 21.9 63.3
G” 64.1 92.9 58.3 70.9 87 86.1 -61.3 18.8 44.9 -26.5 -8 61.9 53.4
H” 53.8 85.6 9.6 15.1 1.5 87.1 62
I” -28.9 2.8 24.1 10.4 16.4 63.2 81.8
J” 95.9 -15.8 16
K” 10.9
L” 99.7 98.9 44.7 92.2 5.1 81.3
M” 89.1 55.7 32.1 93.9 23.2 0.9 95.4 8 63.7
N” 89.7 14.5 14.9 38.4 7 71.3
O” 71.7 91.9 20.9 -0.9 69.2 78.5
P” 1.1 53.5 -2.9 70.6 79.9
Q” 100 54.7 47.1 73
Y” 51
S” 15 48.4 13.4
T” 61.2 17.8 23.9 33.4 32.4 27.2 2 38 83.8 85.5
U” 74.5 17.4 37.5 19 93.5 85.9
V” 26.5 91.2 10.5 6.7 10.5 76.1
W” 74 91.6 1 24.1 5.4 66.8
50% 60% 70% 80% 90% Percent Inhibition at 50 µM
A B C D E F G H I J K L M N O P Q R
A” 68.7 37.3 75.6 41.7
B” 72.2 70.4 74 54.1 90
C” 84.8 64
D” 80.7 94.6 86.3 39 79.5
E”
F”
G” 64.4 76.2 46.4
H” 41.2 92
I” 69.4
J” 81.3
K”
L” 93.3 87.2 98.5 72.7
M” 83.7 82 86.2
N” 70.5
O” 61.1 78
P” 72.4
Q” 87.3
Y”
S”
T” 101 102
U” 100 77.1
V” 80.9 65.3
W” 88.7
50% 60% 70% 80% 90% Percent Inhibition
Percent Inhibition
at 100 μM
This graph shows 
the percent 
inhibition between 
the coupled product 
of the epoxides A-R 
and thiol A”-W”. 
Percent Inhibition
at 50 μM
This graph shows 
the percent 
inhibition between 
the coupled product 
of the epoxides A-R 
and thiol A”-W”. 
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50% 60% 70% 80% 90% Percent Inhibition at 25 µM
A B C D E F G H I J K L M N O P Q R
A” 21.6 -11.4 42.6 20.9
B” 37.5 25.6 27.1 11.29 57.8
C” 78.8 35.1
D” 59.6 81.4 39.5 51.8 72.7
E”
F”
G” 31.4 37.2
H” 48.2 56.2
I” 55.7
J” 52.6
K”
L” 68.2 64.8 67.8 62.3
M” 67.2 50.7 68
N” 39.7
O” 38 42.5
P” 60.3
Q” 68.5
Y”
S”
T” 90.1 86.7
U” 85.1 72.4
V” 54.8 44.9
W” 72.6
50% 60% 70% 80% 90% Percent Inhibition
Percent Inhibition
at 25 μM
This graph shows 
the percent 
inhibition between 
the coupled product 
of the epoxides A-R 
and thiol A”-W”. 
